share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju

SEC announcement ·  Mar 23 05:48
Summary by Futu AI
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG, was involved in a transaction with the company's stock on March 20, 2024. The specific details of the transaction, such as the action type, status, number of shares, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the potential impact on their investment and the confidence of the company's executives in its future.
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG, was involved in a transaction with the company's stock on March 20, 2024. The specific details of the transaction, such as the action type, status, number of shares, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the potential impact on their investment and the confidence of the company's executives in its future.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.